SCHEMBL22096014

SCHEMBL22096014

O=C(O)c1nonc1NCn1nnnc1CCc1cccc2ccccc12

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
STAT5B P51692 4/20 0.66
COPS5 Q92905 1/20 0.41
SOS1 Q07889 1/20 0.39
MCL1 Q07820 3/20 0.38
ALDH1A1 P00352 4/20 0.36
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HTT P42858 1/20 0.35
MTNR1A P48039 1/20 0.34
PKM P14618 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
DHODH Q02127 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22096030 0.85 STAT5B (0.82) STAT5BALDH1A1HPGDKMT2ACYP1A2
SCHEMBL20047849 0.81 STAT5B (0.78) STAT5BALDH1A1HPGDKMT2ACYP1A2
SCHEMBL22096031 0.81 STAT5B (0.78) STAT5BALDH1A1HPGDKMT2ACYP1A2
SCHEMBL22096036 0.79 STAT5B (0.69) STAT5BALDH1A1KMT2AHTTMTNR1A
SCHEMBL22096029 0.78 STAT5B (0.79) STAT5BALDH1A1KDM4ECYP1A2CYP2C9
SCHEMBL22096032 0.77 STAT5B (0.78) STAT5BALDH1A1HPGDKMT2AKDM4E
SCHEMBL22096035 0.77 STAT5B (0.72) STAT5BALDH1A1KMT2AHTTPKM
SCHEMBL22096011 0.76 STAT5B (0.88) STAT5BALDH1A1
SCHEMBL22096039 0.76 STAT5B (0.77) STAT5BALDH1A1HPGDKMT2AHTT
SCHEMBL22096016 0.76 STAT5B (0.81) STAT5BALDH1A1HPGDHTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FREIE UNIVERSITAET BERLIN (DE) 2020-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FLT3, MCL1, MYD88 STAT5B 59/4885COPS5 1199/4885SOS1 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.